0R6Y Stock Overview
Produces and supplies alpha-particle emitters for cancer therapy in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Thor Medical ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.63 |
| 52 Week High | NOK 1.45 |
| 52 Week Low | NOK 1.01 |
| Beta | 0 |
| 11 Month Change | 97.07% |
| 3 Month Change | 154.73% |
| 1 Year Change | 101.92% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 31.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R6Y | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 43.8% | 1.5% | 2.2% |
| 1Y | 101.9% | -17.9% | 8.8% |
Return vs Industry: 0R6Y exceeded the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0R6Y exceeded the UK Market which returned 8.3% over the past year.
Price Volatility
| 0R6Y volatility | |
|---|---|
| 0R6Y Average Weekly Movement | 21.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R6Y's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0R6Y's weekly volatility has increased from 14% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 5 | Jasper Kurth | www.thormedical.no |
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA Fundamentals Summary
| 0R6Y fundamental statistics | |
|---|---|
| Market cap | NOK 601.24m |
| Earnings (TTM) | -NOK 18.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-32.4x
P/E RatioIs 0R6Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R6Y income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 18.56m |
| Earnings | -NOK 18.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0R6Y perform over the long term?
See historical performance and comparison